Ravil M Huseynov1, Samir S Javadov2, Ali Osmanov3, Shahin Khasiyev4, Samira R Valiyeva5, Esmira Almammadova5, David W Denning3. 1. The Department of Medical Microbiology and Immunology, Azerbaijan Medical University, Mardanov Qardashlari 98, Baku, Azerbaijan. 2. The Department of Medical Microbiology and Immunology, Azerbaijan Medical University, Baku, Azerbaijan. 3. Global Action Fund for Fungal Infections, Geneva, Switzerland. 4. The Department of Informatics and Statistics, Ministry of Health of Azerbaijan Republic, Baku, Azerbaijan. 5. Republican Centre for Combating AIDS, Ministry of Health of Azerbaijan Republic, Baku, Azerbaijan.
Abstract
BACKGROUND: Azerbaijan is an upper middle-income country in South Caucasus with an area of 86,600 km2 and a total population of 10 million people and gross domestic product of US $4480 per capita. The aim of this research is to estimate fungal infection burden and highlight the problem at national and international levels. METHODS: Fungal infection burden was estimated using data from epidemiological papers and population at risk and LIFE (Leading International Fungal Education) modelling. RESULTS: The number of people living with human immunodeficiency virus (PLHIV) in 2018 was 6193, 29% of them not receiving antiretroviral therapy. Based on 90% and 20% rates of oral and oesophageal candidiasis in patients with CD4 cell count <200 µl-1 we estimate 808 and 579 patients with oral and oesophageal candidiasis, respectively. The annual incidences of cryptococcal meningitis and Pneumocystis pneumonia are 5 and 55 cases, respectively. We estimated 2307 cases of chronic pulmonary aspergillosis (CPA), 4927 patients with allergic bronchopulmonary aspergillosis (ABPA), and 6504 with severe asthma with fungal sensitization (SAFS). Using data on chronic obstructive pulmonary diseases (COPD), lung cancer, acute myeloid leukaemia rates, and number of transplantations, we estimated 693 cases of invasive aspergillosis following these conditions. Using a low-European rate for invasive candidiasis, we estimated 499 and 75 patients with candidemia and intra-abdominal candidiasis respectively. The number of adult women (15-55 years) in Azerbaijan is ~2,658,000, so it was estimated that 159,490 women suffer from recurrent vulvovaginal candidiasis (rVVC). DISCUSSION: In total, the estimated number of people suffering from fungal diseases in Azerbaijan is 225,974 (2.3% of the population). However, the fungal rate is underestimated due to lack of epidemiological data. The most imminent need is improvement in diagnostic capabilities. This aim should be achieved via establishing a reference laboratory and equipping major clinical centers with essential diagnostics assays.
BACKGROUND: Azerbaijan is an upper middle-income country in South Caucasus with an area of 86,600 km2 and a total population of 10 million people and gross domestic product of US $4480 per capita. The aim of this research is to estimate fungal infection burden and highlight the problem at national and international levels. METHODS: Fungal infection burden was estimated using data from epidemiological papers and population at risk and LIFE (Leading International Fungal Education) modelling. RESULTS: The number of people living with human immunodeficiency virus (PLHIV) in 2018 was 6193, 29% of them not receiving antiretroviral therapy. Based on 90% and 20% rates of oral and oesophageal candidiasis in patients with CD4 cell count <200 µl-1 we estimate 808 and 579 patients with oral and oesophageal candidiasis, respectively. The annual incidences of cryptococcal meningitis and Pneumocystis pneumonia are 5 and 55 cases, respectively. We estimated 2307 cases of chronic pulmonary aspergillosis (CPA), 4927 patients with allergic bronchopulmonary aspergillosis (ABPA), and 6504 with severe asthma with fungal sensitization (SAFS). Using data on chronic obstructive pulmonary diseases (COPD), lung cancer, acute myeloid leukaemia rates, and number of transplantations, we estimated 693 cases of invasive aspergillosis following these conditions. Using a low-European rate for invasive candidiasis, we estimated 499 and 75 patients with candidemia and intra-abdominal candidiasis respectively. The number of adult women (15-55 years) in Azerbaijan is ~2,658,000, so it was estimated that 159,490 women suffer from recurrent vulvovaginal candidiasis (rVVC). DISCUSSION: In total, the estimated number of people suffering from fungal diseases in Azerbaijan is 225,974 (2.3% of the population). However, the fungal rate is underestimated due to lack of epidemiological data. The most imminent need is improvement in diagnostic capabilities. This aim should be achieved via establishing a reference laboratory and equipping major clinical centers with essential diagnostics assays.
Authors: Kate Buchacz; Rose K Baker; Frank J Palella; Joan S Chmiel; Kenneth A Lichtenstein; Richard M Novak; Kathleen C Wood; John T Brooks Journal: AIDS Date: 2010-06-19 Impact factor: 4.177
Authors: Alexandra Fochtmann; Christina Forstner; Michael Hagmann; Maike Keck; Gabriela Muschitz; Elisabeth Presterl; Gerald Ihra; Thomas Rath Journal: Burns Date: 2014-09-17 Impact factor: 2.744
Authors: Carlos Rodriguez; Amy C Weintrob; James R Dunne; Allison B Weisbrod; Bradley Lloyd; Tyler Warkentien; Debra Malone; Justin Wells; Clinton K Murray; William Bradley; Faraz Shaikh; Jinesh Shah; Michelle Leigh Carson; Deepak Aggarwal; David R Tribble Journal: J Trauma Acute Care Surg Date: 2014-11 Impact factor: 3.313
Authors: Alexander F A D Schauwvlieghe; Bart J A Rijnders; Nele Philips; Rosanne Verwijs; Lore Vanderbeke; Carla Van Tienen; Katrien Lagrou; Paul E Verweij; Frank L Van de Veerdonk; Diederik Gommers; Peter Spronk; Dennis C J J Bergmans; Astrid Hoedemaekers; Eleni-Rosalina Andrinopoulou; Charlotte H S B van den Berg; Nicole P Juffermans; Casper J Hodiamont; Alieke G Vonk; Pieter Depuydt; Jerina Boelens; Joost Wauters Journal: Lancet Respir Med Date: 2018-07-31 Impact factor: 30.700
Authors: J Guinea; M Torres-Narbona; P Gijón; P Muñoz; F Pozo; T Peláez; J de Miguel; E Bouza Journal: Clin Microbiol Infect Date: 2009-11-10 Impact factor: 8.067
Authors: R Rautemaa-Richardson; V Rautemaa; F Al-Wathiqi; C B Moore; L Craig; T W Felton; E G Muldoon Journal: J Antimicrob Chemother Date: 2018-12-01 Impact factor: 5.790